Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.

Cancer cell movement during metastasis is a dynamic process regulated by several different signals. However, the way cells receive, process and respond to these signals has been extremely hard to detect, but is now made easier by a new visualisation tool.

AI tools can provide close to precise survival estimates of patients with prostate cancer, according to scientists

Scientists have identified why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and developed a new combination therapy. Identifying this mechanism is important as it identifies patients who will not respond to single agent ICB treatment such as anti-PD1 antibody therapy, but are most likely to benefit from the new combination therapy that they have identified, anti-CD30. By simply adding anti-CD30 for these patients, they believe they can improve response to cancer and avoid costly delays.